Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 38Squamous Cell Carcinoma of Head and Neck 23Uterine Cervical Neoplasms 18Head and Neck Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 13Central Nervous System Neoplasms 13Stomach Neoplasms 12Mesothelioma, Malignant 12Neuroblastoma 11Oropharyngeal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Ovarian Neoplasms 9Carcinoma, Ovarian Epithelial 9Urinary Bladder Neoplasms 8Adenocarcinoma of Lung 8Testicular Neoplasms 7Mouth Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Testicular Germ Cell Tumor 6Lymphoma, Large-Cell, Immunoblastic 6Carcinoma 6Astrocytoma 6Teratoma 5Small Cell Lung Carcinoma 5Peritoneal Neoplasms 5Oligodendroglioma 5

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Complete Response × Cisplatin × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡